Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance
Key result
New ApoC-III therapies substantially reduce triglycerides to target a causal driver of CVD.
Why the study?
A residual cardiovascular risk persists in patients with optimal LDL-C levels, driven in part by elevated triglycerides and triglyceride-rich lipoproteins regulated by apolipoprotein C-III.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Should not yet change triglyceride management; leaves open the cardiovascular benefit of apolipoprotein C-III inhibition pending outcome trials.
Key Points
- To examine the biological mechanisms of apolipoprotein C-III in triglyceride metabolism and evaluate novel therapeutics designed to target it.
- Narrative review synthesizing mechanistic insights into apolipoprotein C-III (apoC-III) function and regulation of triglyceride-rich lipoproteins.
- Evaluation of human genetic studies, specifically APOC3 loss-of-function variants and their correlation with coronary heart disease risk.
- Assessment of emerging pharmacological agents targeting apoC-III, including antisense oligonucleotides, small interfering RNA, and monoclonal antibodies.
- ApoC-III raises circulating triglycerides by inhibiting lipoprotein lipase activity and interfering with hepatic clearance of triglyceride-rich lipoproteins.
- Human loss-of-function mutations in the APOC3 gene associate with significantly lower circulating triglyceride concentrations and reduced risk of coronary heart disease.
- Novel targeted therapies, including antisense oligonucleotides, small interfering RNA, and an antibody, achieve substantial reductions in triglyceride levels compared to conventional lipid-lowering therapies.
PICO
P
Population
Atherosclerosis-related cardiovascular disease
I
Intervention / Comparator
Apolipoprotein C-III targeted therapies
This review highlights the pathophysiological role of apolipoprotein C-III in cardiovascular disease and the potential of emerging pharmacological therapies targeting it to reduce residual cardiovascular risk.
Cite This Study
Packard et al. (2023) conducted a review in Atherosclerosis-related cardiovascular disease. Apolipoprotein C-III targeted therapies was evaluated. Apolipoprotein C-III is a key regulator of triglyceride metabolism causally linked to cardiovascular disease, and new targeted therapies can substantially reduce triglyceride levels.